BAVA:CPH
Bavarian Nordic A/S
241,00 DKK
arrow_downward
−0,08%(−0,20) 1D
13. lis, 10:37:51 GMT+2 · DKK
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za BAVA...
Otvori
240,00 DKK
Najviša
242,20 DKK
Najniža
240,00 DKK
Trž. kap.
18,77 mlr.
Prosj. kol.
179,17 tis.
Količina
31,47 tis.
52-tjed. najviša
243,70 DKK
52-tjed. najniža
171,30 DKK
Dionice u optjecaju
79,27 mil.
Broj djelatnika
2 tis.
Otvori
240,00 DKK
Najviša
242,20 DKK
Najniža
240,00 DKK
Trž. kap.
18,77 mlr.
Prosj. kol.
179,17 tis.
Količina
31,47 tis.
52-tjed. najviša
243,70 DKK
52-tjed. najniža
171,30 DKK
Dionice u optjecaju
79,27 mil.
Broj djelatnika
2 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
GlobeNewswire
·
prije 16 sati
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Bavarian Nordic A/S – informacije
Glavni izvršni direktorPaul Chaplin
Zaposlenici1,91 tis.
Osnovano1. srp 1992.
Sjedište-
Sektor-
Web-lokacijabavarian-nordic.com